Spasticity and Intrathecal Baclofen

Abstract

Severe spastic tone and/or spastic hypertonia can be the most disabling consequences of a neurologic insult, resulting from an excess of muscle tone. Baclofen, a GABA-B agonist, is one of the most widely used drugs in treating abnormal or disabling spastic tone. However, the effectiveness of baclofen taken orally is often limited by its systemic side effects, including sedation, confusion, and lethargy. Intrathecal baclofen (ITB) delivered by an implanted catheter can work directly at the spinal cord level to reduce spastic tone through presynaptic inhibition. Several decades after Penn and Kroin (1984) proved that continuous infusion of intrathecal baclofen reduced spinal cord spasticity, numerous studies have demonstrated the benefits of ITB therapy and proven its effectiveness in modulating and reducing spastic tone. In this article the authors review current methods of management with ITB therapy; summarize the current knowledge, controversies, and available scientific literature; illustrate through different clinical cases treatment strategies and their outcomes; and lastly, provide a synopsis of current clinical practice in ITB therapy with insights into new therapeutic developments.

Keywords

intrathecal - baclofen - spastic tone - GABA - hypertonia - hyperreflexia - infusion mode

• References

• 1 Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW ; Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111 (1) e89-e97
• 2 Ghai A, Garg N, Hooda S, Gupta T. Spasticity - Pathogenesis, prevention and treatment strategies. Saudi J Anaesth 2013; 7 (4) 453-460
• 3 Sheean G, McGuire JR. Spastic hypertonia and movement disorders: pathophysiology, clinical presentation, and quantification. PM R 2009; 1 (9) 827-833
• 4 Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature 1981; 290 (5802) 149-152
• 5 Francisco GE. Intrathecal baclofen therapy for stroke-related spasticity. Top Stroke Rehabil 2001; 8 (1) 36-46
• 6 Francisco GE, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil 2003; 84 (8) 1194-1199
• 7 Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 2001; 32 (9) 2099-2109
• 8 Knutsson E, Lindblom U, Mårtensson A. Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci 1974; 23 (3) 473-484
• 9 Müller H, Zierski J, Dralle D, Krauss D, Mutschler E. Pharmacokinetics of intrathecal baclofen. In: Local-Spinal Therapy of Spasticity. Heidelberg, Germany: Springer; 1988: 223-226
• 10 Albright AL, Shultz BL. Plasma baclofen levels in children receiving continuous intrathecal baclofen infusion. J Child Neurol 1999; 14 (6) 408-409
• 11 Penn RD, Kroin JS. Long-term intrathecal baclofen infusion for treatment of spasticity. J Neurosurg 1987; 66 (2) 181-185
• 12 Ochs GA, Reimann IW, Meinck H-M. Baclofen Intrathekal: Leitfaden für die Praktische Anwendung, Germany: Georg Thieme; 1995
• 13 Misgeld U, Bijak M, Jarolimek W. A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 1995; 46 (4) 423-462
• 14 Albright AL, Barry MJ, Shafton DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001; 43 (10) 652-657
• 15 Pandyan AD, Cameron M, Powell J, Stott DJ, Granat MH. Contractures in the post-stroke wrist: a pilot study of its time course of development and its association with upper limb recovery. Clin Rehabil 2003; 17 (1) 88-95
• 16 Twitchell TE. The restoration of motor function following hemiplegia in man. Brain 1951; 74 (4) 443-480
• 17 Ward NS, Brown MM, Thompson AJ, Frackowiak RS. Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain 2003; 126 (Pt 11) 2476-2496
• 18 O'Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. Brain 1996; 119 (Pt 5) 1737-1749
• 19 Schiess MC, Oh IJ, Stimming EF , et al. Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation 2011; 14 (1) 38-45 , discussion 45
• 20 Graham LA. Management of spasticity revisited. Age Ageing 2013; 42 (4) 435-441
• 21 Pandyan AD, Gregoric M, Barnes MP , et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005; 27 (1-2) 2-6
• 22 Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67 (2) 206-207
• 23 Jose A, Luciano P, Vicente V, Juan Marcos AS, Gustavo F-C. Role of catheter's position for final results in intrathecal drug delivery. Analysis based on CSF dynamics and specific drugs profiles. Korean J Pain 2013; 26 (4) 336-346
• 24 Rawlins PK. Intrathecal baclofen therapy over 10 years. J Neurosci Nurs 2004; 36 (6) 322-327
• 25 Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984; 1 (8385) 1078
• 26 Meythaler JM, DeVivo MJ, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil 1996; 77 (5) 461-466
• 27 Grabb PA, Guin-Renfroe S, Meythaler JM. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery 1999; 45 (4) 833-836 , discussion 836–837
• 28 Albright AL. Spasticity and movement disorders in cerebral palsy. J Child Neurol 1996; 11 (1) (Suppl. 01) S1-S4
• 29 Mathur SN, Chu SK, McCormick Z, Chang Chien GC, Marciniak CM. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. PM R 2014; 6 (6) 506-513 , e1
• 30 Saval A, Chiodo AE. Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin. J Spinal Cord Med 2010; 33 (1) 16-21
• 31 Dietz V, Sinkjaer T. Spastic movement disorder: impaired reflex function and altered muscle mechanics. Lancet Neurol 2007; 6 (8) 725-733
• 32 Draulans N, Vermeersch K, Degraeuwe B , et al. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil 2013; 27 (12) 1137-1143
• 33 Rekand T, Grønning M. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med 2011; 43 (6) 511-514
• 34 Ridley B, Rawlins PK. Intrathecal baclofen therapy: ten steps toward best practice. J Neurosci Nurs 2006; 38 (2) 72-82
• 35 Gilmartin R, Bruce D, Storrs BB , et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000; 15 (2) 71-77
• 36 Albright AL, Ferson SS. Intrathecal baclofen therapy in children. Neurosurg Focus 2006; 21 (2) e3
• 37 Turner M, Nguyen HS, Cohen-Gadol AA. Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations. J Neurosurg Pediatr 2012; 10 (4) 315-319